Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab

被引：14

作者：

Meunier, Benoit ^{[2
]}

Rico, Audrey ^{[1
]}

Seguier, Julie ^{[2
]}

Boutiere, Clemence ^{[1
]}

Ebbo, Mikael ^{[2
]}

Harle, Jean Robert ^{[2
]}

Schleinitz, Nicolas ^{[2
]}

Pelletier, Jean ^{[1
]}

机构：

[1] Hop La Timone, AP HM, Pole Neurosci Clin, Serv Neurol, F-13385 Marseille, France

[2] Hop La Timone, AP HM, Dept Med Interne, Marseille, France

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷 / 06期

关键词：

Multiple sclerosis; alemtuzumab; hemolytic anemia; CONTROLLED PHASE-3 TRIAL;

D O I：

10.1177/1352458517729766

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS). Objective: To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male. Methods: Case report. Results: A 28-year-old male developed a life-threatening autoimmune anemia occurring 11months after first alemtuzumab course. Conclusion: We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert.

引用

页码：811 / 813

页数：3

共 9 条

[1] Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis [J].

Azzopardi, Laura ;

Thompson, Sara A. J. ;

Harding, Katherine E. ;

Cossburn, Mark ;

Robertson, Neil ;

Compston, Alastair ;

Coles, Alasdair J. ;

Jones, Joanne L. .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (07) :795-798

[2]

Cheung Winnie W, 2006, Haematologica, V91, pECR13

[3] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial [J].

Cohen, Jeffrey A. ;

Coles, Alasdair J. ;

Arnold, Douglas L. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Fisher, Elizabeth ;

Brinar, Vesna V. ;

Giovannoni, Gavin ;

Stojanovic, Miroslav ;

Ertik, Bella I. ;

Lake, Stephen L. ;

Margolin, David H. ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1819-1828

[4] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial [J].

Coles, Alasdair J. ;

Twyman, Cary L. ;

Arnold, Douglas L. ;

Cohen, Jeffrey A. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Miller, Tamara ;

Fisher, Elizabeth ;

Sandbrink, Rupert ;

Lake, Stephen L. ;

Margolin, David H. ;

Oyuela, Pedro ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1829-1839

[5] A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis [J].

Cuker, Adam ;

Coles, Alasdair J. ;

Sullivan, Herman ;

Fox, Edward ;

Goldberg, Mark ;

Oyuela, Pedro ;

Purvis, Annie ;

Beardsley, Diana S. ;

Margolin, David H. .

BLOOD, 2011, 118 (24) :6299-6305

[6] Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients [J].

Elimelakh, Milena ;

Dayton, Vanessa ;

Park, Katharine S. ;

Gruessner, Angelika C. ;

Sutherland, David ;

Howe, Robert B. ;

Reding, Mark T. ;

Eastlund, Ted ;

van Burik, Jo-Anne ;

Singleton, Timothy P. ;

Gruessner, Rainer W. ;

Key, Nigel S. .

HAEMATOLOGICA, 2007, 92 (08) :1029-1036

[7] Guidelines for submitting adverse event reports for publication [J].

Kelly, William N. ;

Arellano, Felix M. ;

Barnes, Joanne ;

Bergman, Ulf ;

Edwards, I. Ralph ;

Fernandez, Alina M. ;

Freedman, Stephen B. ;

Goldsmith, David I. ;

Huang, Kui ;

Jones, Judith K. ;

McLeay, Rachel ;

Moore, Nicholas ;

Stather, Rosie H. ;

Trenque, Thierry ;

Troutman, William G. ;

van Puijenbroek, Eugene ;

Williams, Frank ;

Wise, Robert P. .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (05) :581-587

[8] CAMPATH-1H, A HUMANIZED MONOCLONAL-ANTIBODY, IN REFRACTORY RHEUMATOID-ARTHRITIS - AN INTRAVENOUS DOSE-ESCALATION STUDY [J].

WEINBLATT, ME ;

MADDISON, PJ ;

BULPITT, KJ ;

HAZLEMAN, BL ;

UROWITZ, MB ;

STURROCK, RD ;

COBLYN, JS ;

MAIER, AL ;

SPREEN, WR ;

MANNA, VK ;

JOHNSTON, JM .

ARTHRITIS AND RHEUMATISM, 1995, 38 (11) :1589-1594

[9] Alemtuzumab for Multiple Sclerosis [J].

Willis, Mark D. ;

Robertson, Neil P. .

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (09)

← 1 →